LYPLA2 and inflammatory bowel disease: Dysfunctional differentiation of TH17 cells has an important pathogenic role in IBD, including ulcerative colitis and Crohn’s disease; therefore, both DHHC7 and APT2 could be new therapeutic targets for IBD treatment.